Review Article
Role of miRNA Let-7 and Its Major Targets in Prostate Cancer

Siegfried Wagner,1,2 Anaclet Ngezahayo,2 Hugo Murua Escobar,1,3 and Ingo Nolte1

1 Small Animal Clinic, University of Veterinary Medicine Hannover, 30559 Hannover, Germany
2 Institute of Biophysics, University Hannover, 30419 Hannover, Germany
3 Division of Medicine, Department of Haematology/Oncology, University of Rostock, 18057 Rostock, Germany

Correspondence should be addressed to Ingo Nolte; ingo.nolte@tiho-hannover.de

Received 16 April 2014; Revised 11 August 2014; Accepted 18 August 2014; Published 3 September 2014

Academic Editor: Andreas Doll

Copyright © 2014 Siegfried Wagner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prostate cancer is worldwide the sixth leading cause of cancer related death in men thus early detection and successful treatment are still of major interest. The commonly performed screening of the prostate-specific antigen (PSA) is controversially discussed, as in many patients the prostate-specific antigen levels are chronically elevated in the absence of cancer. Due to the unsatisfying efficiency of available prostate cancer screening markers and the current treatment outcome of the aggressive hormone refractory prostate cancer, the evaluation of novel molecular markers and targets is considered an issue of high importance. MicroRNAs are relatively stable in body fluids orchestrating simultaneously the expression of many genes. These molecules are currently discussed to bear a greater diagnostic potential than protein-coding genes, being additionally promising therapeutic drugs and/or targets. Herein we review the potential impact of the microRNA let-7 family on prostate cancer and show how deregulation of several of its target genes could influence the cellular equilibrium in the prostate gland, promoting cancer development as they do in a variety of other human malignant neoplasias.

1. Introduction

Prostate cancer (PC) is a heterogeneous disease ranging from an asymptomatic to a fatal systemic malignancy [1]. According to the World Health Organization (WHO) 1,111,689 men were estimated to be diagnosed with PC in the year 2012 (http://globoCan.iarc.fr/). Accounting worldwide for 6.6% (307,471) of all cancer death in men in 2012, PC is one of the most common malignant neoplasias and the sixth leading cause of cancer related death in men (http://globoCan.iarc.fr/).

The development of PC is considered to be a multi-step process initiated by genetic and epigenetic changes [1]. Human PC is commonly accepted to be an androgen dependent malignancy.

An analysis of PC related metastatic pattern in 1,589 patients by Bubendorf et al. revealed that 35% of the analyzed tumors spread to other organs with preference to the bones (90%), lungs (46%), liver (25%), pleura (21%), and adrenals (13%) [2].

The androgen deprivation therapy is actually the most effective palliative standard treatment for primary advanced PCs with bone metastasis (effective in up to ~90% of patients). However, the great majority of patients relapse subsequently due to the development of castration resistance [3].

Since the introduction of the prostate-specific antigen (PSA) test in the 1990s, the number of diagnosed cases has been rapidly rising being initially associated with a reduced mortality. However, the recent decline in PC related mortality rates is now being discussed to be partially explained by the improved treatment and earlier diagnosis due to a broad standard PSA screening in economically developed countries [4, 5]. As the standard PSA screening in the early diagnosis of human PC remains a very controversial issue, novel, reliable molecular PC markers are needed [6–8].

A promising marker candidate gene is the miRNA let-7, which was reported to be down regulated among others in human PC [9–11]. Further, the reconstitution of the let-7 expression resulted in suppression of PC cell proliferation [10, 12]. In general a single miRNA is able to regulate a huge number of genes. Concerning let-7 the respective acting ways are actually not entirely deciphered.
Nevertheless, it is to be expected that a deeper understanding of the molecular interactions of let-7 and associated genes will significantly contribute to the development of novel diagnostic and therapeutic treatment modalities for PC.

Due to the complex regulation mechanisms of let-7 and its potential role in PC development and relapse the present review highlights let-7 and its direct and downstream targets in the context of PC.

2. Micro RNA Let-7 Family

MicroRNAs (miRNAs) are small, non-protein-coding RNAs derived from long, endogenously expressed primary RNA (pri-miRNA) molecules. These pri-miRNAs are processed by the nuclear enzyme Drosha to precursor RNAs (pre-miRNAs), exported by Exprotin-5 [13] and matured by the cytoplasmic enzyme Dicer [14]. Finally the guide strand of the mature miRNA is incorporated into the RNA-induced silencing complex (RISC), which blocks the translation of the target mRNA by binding to its 5’-3’-prime, or exon regions [15, 16]. The passenger strand is usually degraded [17] (Figure 1).

Mature miRNAs are known to be part of the gene expression regulating machinery at transcriptional [18, 19] and as well posttranscriptional level [13]. It was reported that a single miRNA can orchestrate the expression of several genes and a single gene can be regulated by a set of different miRNAs [20–22]. Several observations suggest that more than 60% of all protein coding genes are regulated by miRNAs [23].

One of the first described members of the large class of non-protein-coding RNAs is let-7 which was the second miRNA discovered and designated as lethal-7 (let-7) according to the phenotype of a let-7 deficient C. elegans mutant [20]. Soon thereafter, further let-7 homologs were identified in a variety of species ranging from vertebrates to mollusks [24].

In contrast to “less complex” organisms such as worms, vertebrates show a higher number of let-7 isoforms coded by different genes [16]. In humans, 13 let-7 family precursor miRNAs were described (let-7a-1, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, mir-R-98, and mir-202) which code for 10 different mature let-7 miRNA isoforms [25].

Although the role of let-7 is still not fully understood, it is evident that the let-7 family members have a distinct expression pattern in animal development [26]. In the embryonic stage the let-7 miRNAs were found to be barely detectable, but having an increased expression in differentiated cells [20, 27]. Furthermore, aberrant let-7 expression was associated with a variety of human diseases as, for example, cardiovascular diseases [28], liver fibrosis [29], lung diseases [30], and cancer [9–12, 26, 31–34]. Interestingly several let-7 family members were found to be located at fragile sites of human chromosomes potentially contributing to aberrant let-7 transcript levels [35].

Cancer initiation, progression, and aggressiveness are hypothesized to be driven by cancer stem cells (CSCs) [36, 37]. Inflammatory microenvironment [38] as well as epithelial-to-mesenchymal transition (EMT), which is tightly linked with CSC biology [39], seems to play a substantial role in cancer etiology as well. Remarkably, a linkage between these factors is the let-7 miRNA family. As described above let-7 was shown to be downregulated in prostatic CSCs [36] whereas reconstitution of the let-7 suppressed the growth of PC cells [10, 12]. Additionally, a direct causal link between cancer and inflammation is given by the association of let-7, IL6, and NFkB, which are major players involved in the epigenetic switch from inflammation to cell transformation [31]. The connection between EMT and let-7 is represented by the HMGA1 and HMGA2 genes, which are directly regulated by let-7 and were found to be implicated in EMT [40, 41].

Further, miRNAs of the let-7 family were reported to directly, negatively regulate IL6 [24], NRAS [42], c-Myc, HMGA1 [43, 44], HMGA2 [45], and CCND2 [11]. Notably, these let-7 targets are involved in a wide range of diverse cellular processes interwoven with let-7 and each other in a fine balanced way (Figure 10).

The c-Myc protein regulates the biogenesis of let-7 by stimulating Lin28 [46], Lin28 in turn blocks the maturation of let-7 [47]. Additionally, c-Myc stimulates the expression of HMGA1 [48], AR [12], and IL6 [49]. NRAS is suggested to have an impact on HMGA2 biogenesis [45]. HMGA2 on the other hand influences HMGA1, its gene product in turn regulates the expression of c-Myc [50] and HMGB1 [51]. HMGB1 was found to bind the AR promoter [52], AR protein was described itself to stimulate let-7 expression [53] (Figure 10).

Interestingly, the let-7 family [10, 11] and some of its above mentioned targets were already found to be implicated in PC. As let-7 is linked with all these protein-coding genes a deeper insight into these connections is of great interest. Thus, these interactions are reviewed more detailed in the following parts.

3. HMGA1

The high mobility group proteins (HMG) are chromatin associated nonhistone proteins constituting three superfamilies (HMGA, HMGB, and HMGN) which are classified by their characteristic functional DNA-binding motifs [54]. Expression of these proteins was described to be involved in a variety of biological processes as, for example, transcription, embryogenesis, differentiation, neoplastic transformation, apoptosis, and inflammation [52, 55, 56].

In human neoplasias the HMGA genes are among the most commonly rearranged genes [57]. Deregulation of the HMGA1 expression was described in human PC [58, 59], lung cancer [60], and breast cancer cells [61]. Its oncogenic property is speculated to be partly mediated through the cytoplasmic relocation of the HIPK2 which is a proapoptotic activator of the tumor suppressor p53 [51] (Figures 2 and 10). HMGA1 was reported to enhance the proliferation rate and invasion of PC cells [62, 63] potentially through the implication in epithelial-to-mesenchymal transition (EMT) [61]. In line with this, HMGA1 knock down in the human triple-negative breast cancer cell lines MDA-MB-231 and Hs578T
Figure 1: Schematic overview of the miRNA maturation and the way of function in eukaryotic cells. The endogenously expressed primary miRNA (pri-miRNA) is processed in the nucleus of a cell by the enzyme Drosha. The emerging precursor miRNA (pre-miRNA) product is exported into the cytoplasm by Exportin-5 and matured by Dicer. Finally, the guide strand is incorporated into the RNA-induced silencing complex (RISC), which blocks the translation of the target mRNA.

Figure 2: Overview of the described interactions between let-7 and its direct target HMGA1 with other genes.

HMGA1, HMGA2, and of its regulator let-7 was shown to be negatively correlating in gastroenteropancreatic neuroendocrine tumors [44] and retinoblastomas [72]. In accordance they were found to be directly, negatively regulated by let-7 [45, 73, 74] (Figures 2 and 10).

4. HMGA2

Comparable to the described HMGA1 knock down, the repression of HMGA2 in the human PC cell line PC-3 induced an upregulation of CDHI indicating an important role in EMT [41]. SNAI1 and SNAI2 are repressors of CDH1 and were shown to be directly activated by HMGA2 [45] (Figures 3 and 10).
Similar to HMGA1, an upregulation of HMGA2 was reported in human lung and breast cancers [75, 76] as well as in a subset of canine PCs [77]. Furthermore, HMGA2 was recently described to modify gene expression not only as protein but as well as a competing endogenous RNA (ceRNA) by acting as a decoy for mature let-7 miRNAs [78]. Interestingly, a stimulating HMGA2 influence on the expression of its sister protein HMGA1 was found in rat epithelial thyroid cells [79], thus constituting a feedback loop by the stimulation of its suppressor, the miRNA-196a-2 [66] (Figures 3 and 10). Remarkably HMGA2 was described to bear even let-7-binding sites in its 3'-untranslated region (3' UTR) [33]. Abrasions of the chromosomal region 12q14-15 that affect HMGA2 were frequently found in human cancers [80–82]. Moreover, the disrupted pairing between let-7 and HMGA2 by mRNA truncations of the 3' UTR was reported to induce HMGA2 overexpression leading to tumor formation [33].

5. HMGB1

The high mobility group box 1 (HMGB1) is one of the HMGB superfamily members which was also shown to be implicated in inflammation exercising cytokine like functions [83]. In line with its multiple roles it can be located in the nucleus as well as in the cytoplasm and can even be released passively by necrotic cells or actively secreted in response to inflammatory signals by certain cell types [83, 84].

This proinflammatory cytokine exerts its function by interacting with the toll-like receptors (TLR) 2, and TLR4 and RAGE [85–87] (Figures 4 and 10). Interestingly, the receptor coding gene TLR4 was found to be a direct let-7i target (Figure 4), presenting a mechanism to modify the HMGB1 signaling [88]. The activation of the HMGB1 receptor RAGE results among others in deactivation of MAPK1 and PI3K [89]. PI3K in turn was shown to stimulate NFκB [90]. Furthermore, the TLRs and RAGE were demonstrated to activate NFκB thus, inducing the secretion of angiogenic factors, growth factors, and cytokines [85, 91].

Remarkably, NFκB is able to stimulate RAGE expression by binding to its promoter constituting a positive feedback loop [92] (Figures 4 and 10). Blockade of the RAGE/HMGB1 signaling decreased growth and metastasis of implanted and as well of spontaneously developing tumors in susceptible mice [93].

HMGB1 was described to be involved in all proposed hallmarks of cancer and is thus a potential target for therapeutic and diagnostic approaches [94]. Kuniyasu et al. observed the secretion of HMGB1 in primary cultured human prostatic stromal cells after androgen deprivation [95]. In vitro suppression of HMGB1 was demonstrated to block the invasion of PC-3 cells which was reversed by culturing the cells in conditioned medium of the above-mentioned stromal cells deprived of androgen [95, 96]. Additionally, HMGB1 was found to stimulate DNA binding of several steroid receptors including the let-7 downstream target AR (Figure 10) [97]. These facts indicate that HMGB1 may be a molecular marker for advanced prostate cancer [95, 96].

Although HMGB1 was not shown to be a direct let-7 target, its expression is modulated by the direct let-7 target HMGA1 [51]. Interestingly HMGB1 was also shown to be involved in the p53 network by facilitating the binding of the tumor suppressor p53 to its cognate DNA [98]. As mentioned before p53 can be inactivated by the HMGB1 sister protein HMGA1 by translocation of the p53 activator HIPK2 [51] (Figures 4 and 10). The tumor suppressor p53 in turn was found to downregulate the activity of the HMGB1 promoter [99] and to trigger the radiation induced decrease of let-7a and let-7b expression (Figures 4 and 10) in the human colon cancer cell line HCT116 [100].

6. CCND2

Many tumor cells accumulate mutations resulting in uncontrolled proliferation due to direct or indirect deregulations of the cyclin-dependent kinases (CDKs). Cyclins are known regulating subunits of CDKs being expressed at specific time points during the cell cycle. Consequently cyclin deregulations induce uncontrolled cell proliferation [101].
The cyclin D2 (CCND2) is one of the cell cycle regulating factors. This gene, which is highly conserved among mammals, has been associated with human prostate cancer [11], gastric cancer [102], colon cancer [103], and leukemia [104].

Interestingly, CCND2 was shown to be a direct let-7 and miR-154 target like HMGA2 [11, 41, 45, 105] (Figures 5 and 10). Additionally the let-7 regulated oncogene c-Myc and the stem cell marker Klf4 were reported to stimulate the CCND2 transcription [106, 107] (Figures 5 and 10).

Dong et al. described that ectopically overexpressed let-7a induced cell cycle arrest at the G1/S phase by suppressing among others the cyclin CCND2 and additionally inhibited the proliferation of the human prostatic cell lines PC-3 and LnCap [11]. The same group reported that in nude xenograft mice, inoculated with let-7a transfected PC-3 cells, the tumor was 80% lighter after 4 weeks of growth compared to controls [11].

7. c-Myc

C-Myc is an oncogene frequently activated in human cancers, but is low expressed or absent in quiescent cells [108–110]. In contrast, its overexpression has been connected with PC formation and progression [III, II12]. This gene encodes a transcription factor that has a great impact on the global gene expression pattern and, thus, influences cell-cycle progression, glucose and glutamine metabolism, lipid synthesis, and many other processes, which contribute to tumor progression [109].

Mitogen activated protein kinases (MAPK), glycolgen synthase kinase 3 (GSK3), and other CDKs play a key role in the biological function and half-life of c-Myc proteins by posttranslational phosphorylation of the Thr58 end Ser62 sites [113] (Figures 6 and 10). Apart from various posttranslational protein modifications and transcriptional regulations of the c-Myc gene products, this gene was reported to be directly negatively regulated by members of the let-7 family [114, 115] (Figures 6 and 10). Additionally, elevated MAPK1 activity, which was associated with advanced, androgen independent human PCs, [116] was demonstrated to influence the c-Myc protein, resulting in prolonged function in a human muscle-derived rhabdomyosarcoma cell line [117]. In line with the functions of c-Myc, MAPK1 controls diverse cellular processes as growth, differentiation, migration, and apoptosis, its deregulation has often been described to be associated with cancer [118]. Furthermore, c-Myc was shown to transcriptionally activate Lin28 [119], which in turn inhibits the biogenesis of its regulator let-7 constituting a double negative feedback loop [47] (Figures 6 and 10). Interestingly the expression of the direct let-7 target HMGA1 is as well induced by c-Myc [48], which constitutes a positive feedback loop, stimulating c-Myc expression [50] (Figures 6 and 10).

8. IL6

Chronic inflammation of the prostate gained major attention as it is considered to account to the factors contributing to PC [120]. In previous reports a direct causal link between cancer and inflammation has been described with IL6, let-7, Lin28, and NFκB being the major players involved in the epigenetic switch from inflammation to cell transformation [31].

Originally identified as an inducer of the terminal differentiation of B-cells into antibody-producing cells [121] interleukin-6 (IL6) appears to be a major regulator of prostate cancer progression [122]. Notably, IL6 is not only released by inflammatory cells but also found to be released by hormone insensitive cell lines DU145 and PC-3 but not by the hormone sensitive LNCaP cells [123]. Furthermore, this pleiotropic cytokine stimulates growth and survival of human PC and promotes its progression [123, 124]. In accordance, increased IL6 levels were found in epithelial cells of PC compared to benign tissues [125]. Moreover, Giri et al. reported a ~18 times higher IL6 expression in malignant prostate tissues compared to “normal” prostate specimens [126]. Michalaki and colleagues described significantly higher IL6 serum levels in patients with metastatic prostatic disease [127].

The biological activities of IL6 are mediated by binding to the α-subunit receptor IL6R and the following association with the ubiquitously expressed signal-transducing β-subunit gp130 [128]. Upon engagement of gp130 various Janus tyrosine kinase (JAK) family members (JAK1, JAK2, JAK3, and Tyk2) [129] are activated by ligand induced receptor oligomerization phosphorylating themselves and the intracellular domains of the receptors [130]. Once gp130 is phosphorylated the second protein family, the signal transducer and activator of transcription (STAT), binds to the intracellular domain of the receptor. This leads to the activation of STATs and the subsequent dissociation, allowing...
STAT dimerization and translocation into the nucleus where they act as transcription factors [131]. Additionally, IL6 was shown to stimulate the PI3K and MAPK pathways by signaling through activated gp130 [132, 133].

Interestingly, LnCaP cells stimulated with IL6 presented an enhanced AR activity in the absence of a ligand [134, 135]. The IL6 mediated activation of the human AR was indicated to be mediated by STAT3 and MAPK signaling [134, 136], which potentially contribute to recurrence of hormone refractory PCs. Whereas the AR transactivation can be suppressed by the PI3K/AKT pathway. Thus, these three pathways are suggested to coordinate regulation of AR activation [136].

Acquiring resistance to apoptosis appears an important feature for the development of hormone resistant and aggressive human prostate cancer. Furthermore, IL6 was shown to act as a survival factor, blocking apoptosis induced by Bcl-xl, p53, TGF1b [137], and cytotoxic agents such as doxorubicin [138] and enzalutamide [139]. Whereas siRNA or STAT3-inhibitor-AG490 mediated suppression of the downstream acting STAT diminished the IL6 induced antiapoptotic function [138, 139].

NFkB is a regulator of the transcription of IL6 [140] and Lin28B [31, 141] (Figures 7 and 10). Lin28B was demonstrated to block the maturation of let-7 [46]. Additionally, members of the miRNA let-7 family directly target IL6, which in turn constitutes a positive feedback loop on NFkB [31, 49] (Figures 7 and 10).

Remarkably, while only a few cells express membrane bound IL6R all cells display gp130 on their surface [132]. This is an interesting feature as IL6 can also bind to a soluble IL6R (sIL6R) variant, which interacts in an IL6R agonistic manner with gp130, thus, enabling the stimulation of cells lacking endogenous IL6R [142].

9. RAS

The founding members of the RAS gene superfamily N-RAS, H-RAS, and K-RAS are coding for small GTP-binding proteins [143]. Originally identified as retroviral oncogenes in rat sarcomas, RAS were the first human oncogenes discovered, shown to be mutated in around 30% of all human tumors [144, 145]. The very common mutations in the residues G12, G13, and Q61 lock RAS in a constitutively activated state by impairing the intrinsic GTP hydrolysis [144, 146]. RAS proteins are active when they have bound GTP. By hydrolyzing GTP to GDP they become inactive. The intrinsic GTPase activity of the RAS proteins is very low relying on the help of specialized GTP hydrolysis accelerating factors called GTPase activating proteins (GAP) which increase the hydrolysis by more than 100,000 fold [145].

RAS-GTPs are acting as signal transducers across membranes by binding various effector proteins to stimulate signaling pathways [143, 147]. Among these factors are the Raf serine/threonine MAPKK kinases (ARAF, BRAF, and RAF1) which in turn activate MEK-MAPK cascades [148] (Figures 8 and 10). Accordingly, the mammalian MAPK pathways are estimated to be deregulated in one-third of all human cancers [149]. MAPKs activate cytosolic and nuclear factors like JUN and ELK1, which are regulating FOS expression. JUN and FOS are forming the activator protein 1 (API) and, thus, influencing the expression of proteins such as CCNDs which are involved in cell-cycle progression [150] (Figures 8 and 10).

Furthermore, RAS-GTPs induce the translocation and subsequent activation of phosphatidylinositol 3-kinase (PI3Ks) by binding to its catalytic subunit [151] (Figures 7 and 10). PI3K signaling is one of the most often deregulated systems in human cancer [152]. Taylor et al. described that the PI3K expression is altered in 42% of the primary and in 100% of the metastatic cases in the analyzed set of human prostatic cancers [153]. PI3Ks belong to one of the main effector systems in human cancer [154]. This enzyme type phosphorylates primarily to the 3’-OH group of the membrane bound phosphatidylinositol-4,5-bisphosphate (PIP) to generate the messenger phosphatidylinositol-3,4,5-bisphosphate (PIP3) [154]. PIP3 activates itself several pleckstrin homology domain-containing proteins as Akt by directly binding and recruiting it to the plasma membrane [155]. Ectopic expression of a constitutively active Akt in the thyroid cell line SW579 was reported to significantly increase VEGF levels [156] (Figures 8 and 10). Neovascularization and angiogenesis are essential
features for the progression of a growing tumor VEGF is one of the most important inducers of angiogenesis [157]. Niu et al. demonstrated a positive correlation between VEGF and a constitutively active STAT3 [157]. In accordance, it was found that STAT3 binds to the VEGF promoter [157] (Figures 8 and 10). Additionally, STAT3 was reported to bind the promoter of the let-7 biogenesis regulating gene Lin28, resulting in the concomitant upregulation of the let-7 targets RAS, c-Myc, and HMGAA2 [158].

In human tissues the activation of RAS and Rac-MAPK pathways was described to be induced by the extracellular signal transducer FolH1 [159] (Figures 8 and 10). FolH1 is expressed in most of the human prostate cancers and is thus a potential target for diagnostic and therapeutic strategies [160]. The elicited phosphorylation of MAPK1 and MAPK14 induces in turn the activation of the transcription factor NfkB (Figures 8 and 10) which controls the expression of various genes including the let-7 biogenesis-controlling Lin28 [47] and the cytokine IL6 [31, 161] (Figures 8 and 10). Additionally, NfkB was also shown to enhance the endogenous transcription of the primary miRNAs let-7a-3 and let-7b through NfkB responsive binding sites in the promoter regions [141] (Figures 8 and 10).

Remarkably, Johnson et al. reported numerous let-7 binding sites in the 3'-UTR of the RAS genes [42]. In conclusion the expression of the oncogenes NRAS, KRAS, and HRAS was described to be negatively regulated by several members of the let-7 family [42, 162] (Figures 8 and 10).

10. Androgen Receptor (AR)

The gene of the steroid receptor family member AR [163] is located on the human chromosome X and codes for a ligand-dependent transcription factor [164, 165]. Upon ligand binding it translocates into the nucleus and regulates its target genes by binding to the androgen response elements (AREs) [166, 167]. Expressed in nearly all primary human PCs, AR plays a pivotal role in carcinogenesis of the prostate. At the initial diagnosis the majority of PCs depends on androgens and progress after hormone therapy to an androgen-independent disease [3, 168].

Continuous androgen expression is required to drive prostate gland formation during embryogenesis and later to maintain the normal function and glandular anatomy in adults [169]. In general the androgen mediated effects in prostate gland development are driven by the interaction with ARs [169]. The bypass mechanisms of AR upregulation include among others the HMGB1 enrichment on the AR promoter, which enhances the transcription [52] (Figures 9 and 10), an intracrine androgen production [170, 171] additionally ligand independent AR activation by cytokines or growth factors were reported as well [172]. Furthermore, altered specificity or sensitivity as for example by alternative splicing is discussed [173].

However, the activated AR stimulates the expression of its targets as, for example, the above mentioned VEGF [174] and PSA [175]. PSA is a pivotal downstream target of AR, which is used as biomarker for human PC progression [175]. Interestingly, the frequently observed rising of serum PSA in
castrate-resistant PC patients could in parts be explained by AR activity, which is reexpressed/reactivated in advanced PCs [176]. Remarkably, PSA constitutes a positive feedback loop stimulating AR expression as was demonstrated in vitro [175] (Figures 9 and 10).

Furthermore, Tummala et al. highlighted the impact of the Lin28/let-7/Myc axis on PC and demonstrated that Lin28 activates the AR (Figures 9 and 10) and promotes growth of PC [177].

Remarkably AR was reported to be regulated in a negative way by the miRNA let-7c which suppresses its transcriptional activator c-Myc [12] (Figures 9 and 10). Additionally Lyu et al. described an AR induced upregulation of let-7a, let-7b, let-7c, and let-7d (Figures 9 and 10) in the breast cancer cell lines MDA-MB-231 and MDA-MB-453. At least in the case of let-7a this upregulation is indicated to be triggered by AR binding to AREs located at the let-7a promoter [53] (Figures 9 and 10). Furthermore, it was shown that in these cell lines the expression of the direct let-7a targets c-Myc and KRAS was decreased upon treatment with 5α-dihydrotestosterone and increased after an additional suppression of the miRNA let-7a [53].

The spatiotemporal expression of genes and functions depend highly on the cellular and developmental context. Thus, the impact of a single gene can be completely different between diverse tissues and at different time points in development. Nevertheless elucidation of the above described interactions in PC bears great potential due to the ubiquitous existence of the cellular regulatory elements and the potential interactions in each somatic cell of an organism. This idea is supported by the already found implication of each of the described genes in various human cancers. Furthermore several of the reviewed genes are already used as targets for diagnostic, prognostic, and therapeutic approaches. Thus, the master regulator family let-7 is as well a promising target in cancer of the prostate gland.

For a better overview all described interactions between the master regulator family let-7 and its major targets are summarized in Figure 10.

11. Conclusion

Although the knowledge of the genetic and epigenetic alterations in prostate cancer has significantly increased in the last
decades, its diagnosis and therapy still remains a major challenge. The actually described genetic alterations in prostate cancer give more questions than answers. As we could highlight, the genes reviewed in the present paper are not acting in solitude but are closely interwoven with each other (Figure 10). Remarkably, the miRNA let-7 family members are major players in the regulation of gene expression and appear to contribute greatly to the maintenance of the Ying and Yang in “normal” prostatic cells. However, their impact can be modified greatly by other factors. For that reason the complex intra- and intercellular genetic interactions of let-7 family members and associated genes must be further investigated and will likely have an impact on diagnostic, prognostic, and treatment modalities in future.

Conflict of Interests
The authors have no conflict of interests.

References


